Create Medic (5187) Q3 2026 earnings summary

Executive summary

• 9M 2026 net sales rose 4.1% YoY to ¥10,467 million; operating profit fell 44.2% to ¥509 million and profit attributable to owners of parent declined 54.7% to ¥301 million.

• Comprehensive income increased 82.8% YoY to ¥699 million from ¥382 million.

Financial highlights

• Cost of sales rose 12.8% to ¥6,172 million; gross profit fell 6.3% to ¥4,295 million and SG&A increased 3.2% to ¥3,785 million.

• Ordinary profit declined 34.8% to ¥568 million from ¥871 million.

• Basic EPS was ¥37.05, down from ¥78.45; diluted EPS was ¥33.30, down from ¥76.57.

Outlook and guidance

• FY2026 forecast: net sales ¥13,960 million (+2.5%), operating profit ¥760 million (-24.4%), ordinary profit ¥800 million (-19.0%) and parent-attributable profit ¥560 million (-21.5%).

• FY2026 forecast basic EPS is ¥68.90; no earnings forecast revisions were announced.

• Own-brand plans include expanding H1 launches; European exports are expected to remain firm as MDR transitions progress. India sales operations are starting through a local subsidiary, and OEM sales are expected to grow.

• Medium-term operating-profit targets: ¥1.3 billion and 8% margin in FY2027; ¥3 billion and 15% margin in FY2034.